October 17th 2024
With this combined administration, patients saw noticeable and lasting improvements in severe cases of AD.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cortisol testing demonstrates systemic safety, efficacy for AD
June 1st 2005San Diego — The lipid enhanced, emollient cream formulation of hydrocortisone butyrate 0.1 percent (Locoid, Ferndale) effectively treats moderate to severe atopic dermatitis (AD) in children and does so with excellent systemic safety, at least when used over a period of up to four weeks, said Lawrence F. Eichenfield, M.D., at the Pediatric Dermatology for the Practitioner Meeting here.
Duo offers efficient, effective photon delivery
June 1st 2005Lake Buena Vista, Fla. — Photo-Pneumatic Technology Therapy? (PPx), manufactured by Aesthera Corp., is showing promise as an innovative new approach for enhancing the safety and efficacy of hair removal and nonablative skin rejuvenation procedures, according to Vic A. Narurkar, M.D, who spoke at the Annual Meeting of the American Society for Laser Medicine and Surgery.
Add some acupuncture to your practice
June 1st 2005National report — When traditional approaches fail, many skin conditions may benefit from the addition of a few needles — acupuncture needles, that is. Some physicians are having good success integrating acupuncture into their dermatological practices.
Vitamin D deficiency unlikely, study says
June 1st 2005National report — Results of a study assessing sunlight exposure during winter months in various geographic locations across the United States refute the idea that "safe sun" photoprotection practices are associated with a risk of vitamin D deficiency, says J. Frank Nash, Ph.D., principle scientist, Procter & Gamble Co., Cincinnati.
Medicare woes add to practice difficulties
June 1st 2005Should the cuts take place as planned, 18 percent of physicians surveyed by the American Medical Association say they would stop accepting new Medicare patients; 57 percent would decrease time spent with patients; and 46 percent would reduce staffing levels.
Pilot trial: NB-UVB not enhanced by tacrolimus
May 1st 2005New Orleans — Concomitant topical treatment with tacrolimus 0.1 percent ointment (Protopic, Fujisawa) does not improve the response of generalized vitiligo to narrowband UVB phototherapy, according to the results of a randomized, double-blind, placebo-controlled, pilot study undertaken by researchers at the University of Texas Southwestern Medical Center.
Tacrolimus, UVB therapy synergistic duo
May 1st 2005Nice, France — Results of a comparative, prospective, randomized study undertaken by French dermatologists indicate that topical tacrolimus ointment 0.1 percent (Protopic, Fujisawa) plus phototherapy with a 308-nm excimer laser can be a highly effective combination for the treatment of recalcitrant, localized vitiligo.
West Nile virus skin symptoms documented
May 1st 2005New Orleans — Scientific literature rarely portrays cutaneous manifestations of West Nile virus (WNV) because these manifestations are, by nature, transient. However, a recent case report contains what is only the second publication of these symptoms.
Overuse of black box warnings is scare tactic
May 1st 2005As the Vioxx/Celebrex scandal lays waste to the American healthcare landscape as we know it, the U.S. Food and Drug Administration (FDA) finds itself under relentless pressure to get things right. Congress is demanding more stringent safety standards and even threatening to create a new federal agency to take safety approvals and monitoring out of the FDA's hands.
Candida antifungal performs well in study
April 1st 2005An investigational topical antifungal product containing miconazole nitrate 0.25 percent in a petrolatum/zinc oxide barrier ointment base (Zimycan, Barrier Therapeutics) has demonstrated positive efficacy and safety results in a phase 3 study of the treatment of Candida diaper dermatitis.
Testing identifies key culprits in ACD
April 1st 2005Miami — Bacitracin has been labeled a top cause of allergic contact dermatitis (ACD) in children. Notably, it is an ingredient in Neosporin (Pfizer) and a staple in first aid kits in schools, summer camps and just about every other child-centered environment. Yet private practitioners do not routinely test for this allergen.